Literature DB >> 8432295

Intra-aortic balloon counterpulsation improves survival in cardiogenic shock complicating acute myocardial infarction.

R Waksman1, A T Weiss, M S Gotsman, Y Hasin.   

Abstract

The impact of intra-aortic balloon counterpulsation (IABC) on survival of patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) has been evaluated in this study of 85 patients. IABC was available for the 24 group A patients (and used in 20 patients). IABC was not available for the 21 group B patients who presented simultaneously with similar clinical characteristics and received identical pharmacological treatment. In-hospital and one year survival was significantly higher in group A (46% and 38% vs 19% and 10%, P < 0.001). Sixteen out of the 20 (group A1) IABC patients received early coronary revascularization. During 1980-1984, 35 patients with AMI and CS received IABC (group C) but none underwent early revascularization. There was no difference in in-hospital or one-year survival between group A1 (50% and 40%) and group C (45% and 40%). We conclude that early IABC improves survival of patients with AMI complicated by CS.

Entities:  

Mesh:

Year:  1993        PMID: 8432295     DOI: 10.1093/eurheartj/14.1.71

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  11 in total

Review 1.  Management of cardiogenic shock complicating acute myocardial infarction.

Authors:  Venu Menon; Judith S Hochman
Journal:  Heart       Date:  2002-11       Impact factor: 5.994

2.  Rapid complete reversal of systemic hypoperfusion after intra-aortic balloon pump counterpulsation and survival in cardiogenic shock complicating an acute myocardial infarction.

Authors:  Krishnan Ramanathan; Michael E Farkouh; John E Cosmi; John K French; Shannon M Harkness; Vladimír Džavík; Lynn A Sleeper; Judith S Hochman
Journal:  Am Heart J       Date:  2011-08       Impact factor: 4.749

3.  Thrombolysis in Acute Myocardial Infarction Complicated by Cardiogenic Shock.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 4.  Cardiogenic shock: therapy and prevention.

Authors:  W L Barry; I J Sarembock
Journal:  Clin Cardiol       Date:  1998-02       Impact factor: 2.882

Review 5.  Percutaneous Mechanical Circulatory Support Devices in Cardiogenic Shock.

Authors:  Aditya Mandawat; Sunil V Rao
Journal:  Circ Cardiovasc Interv       Date:  2017-05       Impact factor: 6.546

6.  Effects of intra-aortic balloon counterpulsation pump on mortality of acute myocardial infarction.

Authors:  Liwen Ye; Minming Zheng; Qingwei Chen; Guiqion Li; Wei Deng; Dazhi Ke
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

Review 7.  Impact of Intra-Aortic Balloon Counterpulsation on Prognosis of Patients with Acute Myocardial Infarction: A Meta-Analysis.

Authors:  Zhi-Wei Gao; Ying-Zi Huang; Hong-Mei Zhao; Qing-Song Sun; Man Luo; Li-Qun Pang; Hong Sun
Journal:  Acta Cardiol Sin       Date:  2017-11       Impact factor: 2.672

Review 8.  Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock.

Authors:  Susanne Unverzagt; Michael Buerke; Antoinette de Waha; Johannes Haerting; Diana Pietzner; Melchior Seyfarth; Holger Thiele; Karl Werdan; Uwe Zeymer; Roland Prondzinsky
Journal:  Cochrane Database Syst Rev       Date:  2015-03-27

9.  Intra-aortic balloon pump may grant no benefit to improve the mortality of patients with acute myocardial infarction in short and long term: an updated meta-analysis.

Authors:  Dan Su; Bin Yan; Litao Guo; Liyuan Peng; Xue Wang; Lingfang Zeng; HeanYee Ong; Gang Wang
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

10.  The outcomes of intra-aortic balloon pump usage in patients with acute myocardial infarction: a comprehensive meta-analysis of 33 clinical trials and 18,889 patients.

Authors:  Zhong-Guo Fan; Xiao-Fei Gao; Li-Wen Chen; Xiao-Bo Li; Ming-Xue Shao; Qian Ji; Hao Zhu; Yi-Zhi Ren; Shao-Liang Chen; Nai-Liang Tian
Journal:  Patient Prefer Adherence       Date:  2016-03-16       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.